Pro Dex vs TELA Bio
TELA Bio reported revenue of $80 million in fiscal 2025, about the same as Pro Dex's $78 million in fiscal 2026. Pro Dex's revenue grew 16.4% in its latest year, and TELA Bio's grew 15.8%. Pro Dex had an operating margin of 16.8%, against -42.0% at TELA Bio. Free cash flow was $7 million at Pro Dex and −$29 million at TELA Bio. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.
Side by side
| Pro Dex | TELA Bio | |
|---|---|---|
| Latest fiscal year | FY2026, Jun 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $78M | $80M |
| Revenue growth | 16.4% | 15.8% |
| Revenue growth a year, last 5 years | 15.3% | 34.6% |
| Gross margin | 31.4% | 67.7% |
| Operating margin | 16.8% | −42.0% |
| Net margin | 17.6% | −48.4% |
| Free cash flow | $7M | −$29M |
| Free cash flow margin | 8.7% | −35.7% |
| Return on capital | 19.6% | −190.2% |
| Net debt to EBITDA | 0.6x | — |
| Dividends and buybacks | $3M | $0M |
| Change in diluted share count | −1.3% | 64.6% |
| Last close | $63.49 | $0.73 |
| P/E at the last close | 17.5× | — |
| Insider trades, last 12 months | sold $2.0 million | bought $186,250, sold $0 |
| Piotroski F-score | 7 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Pro DexTELA Bio
Operating margin
Percent of revenue
Pro DexTELA Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Pro DexTELA Bio